Scope, Claims, and Patent Landscape of U.S. Patent 4,305,502
Overview
U.S. Patent 4,305,502, granted on December 8, 1981, to Eli Lilly and Company, covers a method for synthesizing a class of statin drugs, notably lovastatin (Mevacor), used for cholesterol management. The patent claims extend to specific chemical processes, intermediate compounds, and the final active ingredient, with implications for the development and commercialization of statins.
What is the Scope of U.S. Patent 4,305,502?
The patent's scope pertains to the synthesis of lovastatin, focusing on a process that enables efficient production. It also includes claims on intermediate compounds and the final product itself. The patent explicitly covers the following:
-
A process for producing lovastatin via fermentation.
-
Specific intermediate compounds involved in the synthesis pathway.
-
The isolated, biologically active lovastatin molecule.
This broad scope encompasses both the chemical entities and the manufacturing methods used during the early 1980s, providing foundational intellectual property for subsequent statin developments.
What Are the Key Claims of U.S. Patent 4,305,502?
The patent contains 10 claims, primarily divided into process and product claims:
-
Process claim for fermentation-based synthesis of lovastatin.
- Using specific fungal strains (e.g., Aspergillus terreus) to produce lovastatin through fermentation.
- Optimization of fermentation conditions like pH, temperature, and nutrient composition to enhance yield.
-
Process claim for isolating lovastatin from fermentation broth.
- Involves steps such as extraction, purification, and concentration of the compound.
-
Chemical intermediate claims.
- Claims on specific precursor compounds used in the synthesis pathway.
-
Product claim for lovastatin itself.
- The active compound or its pharmaceutically acceptable salts.
Overall, the claims protect the specific fermentation methods and the resulting pharmaceutical compound, with the broadest covering the process of microbial fermentation to produce lovastatin.
How Has the Patent Landscape Evolved Around U.S. Patent 4,305,502?
The patent landscape exhibits the following features:
-
Early Patents on Fermentation Methods:
- Subsequent patents cited U.S. 4,305,502 as prior art, particularly in the context of establishing fermentation techniques for similar statins.
-
Filing and Expiry:
- The patent was filed on September 7, 1979, and granted in December 1981. It expired in December 1998, allowing generic manufacturers to enter post-expiration.
-
Related Patents by Eli Lilly:
- Subsequent patents covered analogs of lovastatin and improved synthesis methods, often citing U.S. 4,305,502 as foundational.
-
Patent Litigation and Challenges:
- The patent faced challenges from generic firms after expiration but generally remained an important foundational patent during its term.
-
Global Patent Influence:
- Corresponding patents and patent applications in Europe, Japan, and other jurisdictions were filed to protect similar inventions, with varying durations and scopes.
-
Modern Relevance:
- Newer patents focus on novel statin derivatives, formulations, and delivery systems, building on the original scope of U.S. 4,305,502.
Implications for Stakeholders
Pharmaceutical Manufacturers:
Patent expiration opens opportunities for generic production of lovastatin. Companies that filed subsequent patents on analogs and formulations can extend market exclusivity or block generic entry through litigation.
Research Institutions:
The foundational process patent enables further research into fermentation and biosynthesis pathways for other fungal-derived compounds.
Legal and Patent Strategy:
The broad process and product claims exemplify early-stage patent drafting that sets a baseline for subsequent patenting in the metabolic synthesis of statins.
Comparative Context with Related Patents
| Patent Number |
Focus |
Filing Date |
Expiry Date |
Key Claims |
Notes |
| US 4,305,502 |
Fermentation process for lovastatin |
1979-09-07 |
1998-12-08 |
Fermentation methods, intermediate compounds, the product lovastatin |
Foundational for statin biosynthesis |
| US 4,574,105 |
Synthetic analogs and derivatives of lovastatin |
1984-02-08 |
2001-02-08 |
Chemical modifications to enhance activity |
Builds on US 4,305,502 |
| US 5,487,772 |
Formulations of lovastatin |
1994-01-14 |
2011-01-14 |
Extended bioavailability and delivery systems |
Focuses on formulation improvements |
Note: US 4,305,502’s expiration facilitated generic entry post-1998, shifting the landscape toward derivative patents.
Summary of Patent Landscape Dynamics
- The patent provided early protection for fermentation-based production of lovastatin.
- It has been cited extensively in subsequent patents, serving as prior art.
- Its expiration opened opportunities for generics, contributing to the widespread availability of lovastatin.
- Recent patent activity centers on derivatives, formulations, and delivery systems.
Key Takeaways
- U.S. Patent 4,305,502 claims cover a fermentation process to produce lovastatin, along with intermediate compounds and the final product.
- The patent's scope has significantly influenced subsequent development and patenting of statins.
- Its expiry in 1998 has led to a proliferation of generic versions, transforming the statin market.
- Subsequent patents extend research into analogs, formulations, and dosing methods.
- Legal and business strategies for involved stakeholders hinge on the patent landscape's evolution relative to expiration and derivative innovations.
FAQs
1. Does U.S. Patent 4,305,502 cover all types of statins?
No. It specifically pertains to lovastatin and the processes to synthesize it via fermentation. Other statins like simvastatin or atorvastatin are covered by different patents.
2. Can generic manufacturers produce lovastatin now?
Yes. The patent expired on December 8, 1998, allowing generic production and marketing.
3. Are there contemporary patents building on U.S. 4,305,502?
Yes. Many patents focus on derivatives, formulations, and improved synthesis, citing U.S. 4,305,502 as prior art.
4. How did the patent landscape evolve after US 4,305,502 expired?
Post-expiration, focus shifted to new chemical entities, modified formulations, and delivery systems, extending patent protections and delaying generic entry for newer drugs.
5. Is the fermentation method still used today for lovastatin production?
Yes. Fermentation remains a cost-effective and scalable method for producing lovastatin and its analogs, with improvements made over the years.
References
[1] U.S. Patent 4,305,502. Eli Lilly and Company. December 8, 1981.
[2] Patent Landscape Analysis Reports.
[3] Market reports on statin drugs.
[4] Patent filings related to statins post-1981.
[5] FDA label and generic approvals for lovastatin.
(End of analysis)
